Can maternofetal transfusion provoke adverse outcomes akin to TA-GVHD?
Carlos Alberto Gonzalez1, Silvana Gonzalez2, Jeremías González3
1Servicio de Hemoterapia, Hospital Muñiz, Uspallata 2272, Buenos Aires, Argentina.
Abstract:
During pregnancy, a bidirectional transfer of molecules and cells takes place through the placenta, which can be considered a transfusion. For decades, we have wondered whether said transfusion can lead to a true TA-GVHD. We propose several factors that may influence production of TA-GVHD during pregnancy. In order to achieve this, we shall take into account possible destinations for transfused leukocytes, which represent extremely different scenarios and may include transfusion associated-graft versus host disease (TA-GVHD).
More Related Videos
Related Concept Videos
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Teratogenicity
Rh Blood Group
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...


